Search Results - "Martin, Ludmila K"

Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone by Dugan, James P, Haverkos, Bradley M, Villagomez, Lynda, Martin, Ludmila K, Lustberg, Mark, Patton, John, Martin, Marisa, Huang, Ying, Nuovo, Gerard, Yan, Fengting, Cavaliere, Robert, Fingeroth, Joyce, Kenney, Shannon C, Ambinder, Richard F, Lozanski, Gerard, Porcu, Pierluigi, Caligiuri, Michael A, Baiocchi, Robert A

“…Primary central nervous system posttransplant lymphoproliferative disorder (PCNS-PTLD) is a complication of solid organ transplantation with a poor prognosis…”
Get full text

Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine‐based therapy with or without bevacizumab by Pant, Shubham, Martin, Ludmila K., Geyer, Susan, Wei, Lai, Van Loon, Katherine, Sommovilla, Nilli, Zalupski, Mark, Iyer, Renuka, Fogelman, David, Ko, Andrew H., Bekaii‐Saab, Tanios

“…BACKGROUND Phase 3 studies of bevacizumab in patients with advanced pancreatic cancer (APCA) demonstrated no improvement in outcome. To the authors' knowledge,…”
Get full text

Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab by Pant, Shubham, Martin, Ludmila K, Geyer, Susan, Wei, Lai, Van Loon, Katherine, Sommovilla, Nili, Zalupski, Mark, Iyer, Renuka, Fogelman, David, Ko, Andrew H, Bekaii-Saab, Tanios

“…Phase III studies of bevacizumab in advanced pancreas cancer (APCA) demonstrated no improvement in outcome. No validated biomarkers for bevacizumab efficacy…”
Get full text

A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors by Martin, Ludmila K, Bekaii-Saab, Tanios, Serna, Derek, Monk, Paul, Clinton, Steven K, Grever, Michael R, Kraut, Eric H

“…This phase I study evaluated the safety of SU5416, a potent and selective inhibitor of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase…”
Get more information

Complete and durable responses in Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone by Dugan, James P., Haverkos, Bradley M., Villagomez, Lynda, Martin, Ludmila K., Lustberg, Mark, Patton, John, Martin, Marisa, Huang, Ying, Nuovo, Gerard, Yan, Fengting, Cavaliere, Robert, Fingeroth, Joyce, Kenney, Shannon C., Ambinder, Richard F., Lozanski, Gerard, Porcu, Pierluigi, Caligiuri, Michael A., Baiocchi, Robert A.

Get full text